Findings from Facts and Factors have authored “Inflammatory Bowel Disease Treatment Market By Product (Crohn Diseases and Ulcerative Diseases), By Route of Administration (Orals and Parental), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Others Pharmacy): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026”. According to estimates, the global Inflammatory Bowel Disease market in 2019 will be worth approximately USD 15,509.22 million. The market is expected to grow at a CAGR of 4.41%, reaching around USD 21,888.23 Million by 2026.

Inflammatory bowel disease is an intestinal disorder characterized by chronic digestive tract inflammation. They are divided into two types: ulcerative colitis and Crohn’s disease. According to data, inflammatory bowel disease affects at least 1.6 million Americans, the majority of whom are under the age of 35. This disorder is classified as chronic; a life-prolonging condition that is easily treated by medicine. These types of disorders primarily affect the individual’s quality of life and, in some cases, their financial well-being.

Inquire more about this report @

Crohn’s disease can affect any part of the GI tract, from the mouth to the anus, but the end of the small intestine is the most commonly affected. Ulcerative colitis primarily affects the large intestine. Injectables and oral medications are prescribed by physicians.

The market is being driven by an increase in global awareness. Furthermore, increasing effective treatment is regarded as one of the major driving factors for market growth. Individual financial burden is one of the major factors influencing market growth. High per capita healthcare expenditure in developed countries, combined with rising per capita income and public awareness in Asia Pacific developing markets, will create enormous opportunities for the market during the forecast period.

The market is divided into two types based on product type. Ulcerative colitis and Crohn’s disease. Crohn’s disease has the largest market share in 2019. Crohn’s disease patients are significantly larger than ulcerative colitis patients. . It is estimated that crohn’s disease will account for more than 65% of the market in 2019.

The market is divided into two types based on the route of drug administration: oral and injectables. Anti-inflammatory drugs are commonly prescribed and administered orally to ulcerative colitis patients. Corticosteroids, antibiotics, immune modulators, and other biologic therapies are also commonly prescribed. The site of administration is determined by the type of drug as well as other factors such as drug efficacy, patient age, and others.

The market is divided into three segments based on end-users: hospital pharmacy, retail pharmacy, and other pharmacy. In 2019, hospital pharmacy had the largest market share. Hospital pharmacies are the primary drug distributors to patients and thus have the largest market share.

The report is divided into five regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa in general. In the year 2019, North America has the largest market share. This expansion will continue during the forecast period. The presence of healthcare infrastructure in this region is primarily responsible for growth. Furthermore, rising per capita healthcare expenditure is a major driver of growth in this region. Countries such as the United Kingdom, Germany, France, and Italy dominate the European region.

Key Players:

Johnson & Johnson Services Inc., Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences are some of the most important market players in the global Inflammatory Bowel Disease Treatment market.

GlobalĀ Inflammatory Bowel Disease Treatment Market: By Region Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East & Africa
    • GCC Countries
    • South Africa
  • Rest of Middle East & Africa

Read also: